Poseida Therapeutics (NASDAQ:PSTX) Receives “Buy” Rating from HC Wainwright

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report released on Thursday, Benzinga reports. They currently have a $20.00 target price on the stock.

Poseida Therapeutics Stock Performance

Poseida Therapeutics stock opened at $2.54 on Thursday. Poseida Therapeutics has a fifty-two week low of $1.83 and a fifty-two week high of $4.27. The company has a market capitalization of $246.27 million, a PE ratio of -2.13 and a beta of 0.51. The company has a 50 day moving average price of $2.86 and a 200-day moving average price of $2.89. The company has a debt-to-equity ratio of 0.97, a quick ratio of 2.48 and a current ratio of 2.48.

Poseida Therapeutics (NASDAQ:PSTX) last issued its earnings results on Monday, August 5th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.11. The business had revenue of $25.97 million during the quarter, compared to analysts’ expectations of $13.75 million. Poseida Therapeutics had a negative return on equity of 121.01% and a negative net margin of 127.48%. As a group, equities analysts forecast that Poseida Therapeutics will post -1.57 earnings per share for the current year.

Institutional Investors Weigh In On Poseida Therapeutics

Large investors have recently modified their holdings of the business. Blair William & Co. IL increased its holdings in Poseida Therapeutics by 41.3% during the first quarter. Blair William & Co. IL now owns 965,052 shares of the company’s stock valued at $3,079,000 after buying an additional 282,310 shares during the period. Renaissance Technologies LLC raised its position in shares of Poseida Therapeutics by 53.4% in the 2nd quarter. Renaissance Technologies LLC now owns 854,900 shares of the company’s stock worth $2,496,000 after acquiring an additional 297,500 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Poseida Therapeutics by 16.3% during the 1st quarter. Vanguard Group Inc. now owns 3,373,065 shares of the company’s stock worth $10,760,000 after purchasing an additional 473,746 shares during the last quarter. Public Employees Retirement System of Ohio boosted its position in Poseida Therapeutics by 177.3% during the first quarter. Public Employees Retirement System of Ohio now owns 62,945 shares of the company’s stock valued at $201,000 after purchasing an additional 40,245 shares in the last quarter. Finally, Lazard Asset Management LLC grew its stake in Poseida Therapeutics by 280.3% in the first quarter. Lazard Asset Management LLC now owns 28,679 shares of the company’s stock valued at $91,000 after purchasing an additional 21,138 shares during the last quarter. Institutional investors own 46.87% of the company’s stock.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.